<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363278">
  <stage>Registered</stage>
  <submitdate>14/11/2012</submitdate>
  <approvaldate>19/11/2012</approvaldate>
  <actrnumber>ACTRN12612001222831</actrnumber>
  <trial_identification>
    <studytitle>Vitamin D3 supplementation in adult patients with non-cystic fibrosis bronchiectasis - a feasibility study</studytitle>
    <scientifictitle>Vitamin D3 supplementation in bronchiectasis - a feasibility study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchiectasis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cholecalciferol 25,000iu single capsule oral dose</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the range of 25(OH) D levels in adult patients with non-cystic fibrosis bronchiectasis and whether vitamin D3 supplementation increases 25(OH) D levels above 75 nmol/L.
Serum samples will be collected at baseline, week 13 and week 26 (end of study) for analysis</outcome>
      <timepoint>Baseline, week 13 and week 26</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate time to first exacerbation and exacerbation frequency after vitamin D3 supplementation.
Patients will be keeping daily diaries to record respiratory symptoms and concomitant medications will be reviewed and recorded at all visits from baseline to week 26</outcome>
      <timepoint>At baseline, week 13 and week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether vitamin D3 supplementation increases lung function.
Spirometry will be performed at all visits from baseline to week 26 for analysis.</outcome>
      <timepoint>At baseline, week 13 and week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether vitamin D3 supplementation improves health-related quality of life measures.

Participants are required to complete the Leicester Cough Questionnaires (LCQ) and CO-OP charts at baseline, week 13 and week 26.</outcome>
      <timepoint>At baseline, week 13 and week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether vitamin D3 supplementation improves chronic rhinosinusitis symptoms.
Nasal endoscopy will be performed at baseline and week 26, Sino-Nasal Outcome Test (SNOT-20) will be completed by participants at baseline, week 13 and week 26.</outcome>
      <timepoint>At baseline, week 13 and week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether vitamin D3 supplementation decreases airway inflammation.
Sputum samples will be collected at baseline and week 26 for analysis of sputum cell counts.</outcome>
      <timepoint>At baseline and week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether vitamin D3 supplementation reduces bacterial infection.
Patients will be keeping daily diaries to record respiratory symptoms and concomitant medications will be reviewed and recorded at all visits from baseline to week 26.</outcome>
      <timepoint>At baseline, week 13 and week 26</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with a diagnosis of bronchiectasis based on high resolution chest CT scan within the previous 2 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients taking Vitamin D3 supplement &gt;600iu per day, patients with cystic fibrosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>All eligible participants who have signed a written informed consent will be allocated to treatment with Vit D3</concealment>
    <sequence>Not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2012</anticipatedstartdate>
    <actualstartdate>18/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/06/2014</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize>31</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/01/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Middlemore Clinical Trials</primarysponsorname>
    <primarysponsoraddress>Private Bag 93311
Otahuhu
Auckland 1640</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland, New Zealand 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to assess the range of 25(OH) D levels in adult patients with non-cystic bronchiectasis and assess whether vitamin D3 supplementation increases 25(OH) D levels above 75 nmol/L</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern A Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of health, 1 The Terrace, PO Box 5013, Wellington 6011</ethicaddress>
      <ethicapprovaldate>31/10/2012</ethicapprovaldate>
      <hrec>12/NTA/41</hrec>
      <ethicsubmitdate>13/09/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Jim Bartley</name>
      <address>Middlemore Hospital
Hospital Road
Otahuhu
Auckland 1640</address>
      <phone>+649 276 0000</phone>
      <fax>+64 9 2763878</fax>
      <email>Jim.Bartley@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Catherine Howie</name>
      <address>Middlemore Clinical Trials
100 Hospital Road
Papatoetoe
Auckland 2025</address>
      <phone>+64 9 2760044 Ext 2017</phone>
      <fax>+64 9 276 3878</fax>
      <email>catherine.howie@mmclintrials.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Howie</name>
      <address>Middlemore Clinical Trials
100 Hospital Rd
Papatoetoe 2025</address>
      <phone>+ 64 9 274 0044 Ext: 2917</phone>
      <fax>+64 9 2763878</fax>
      <email>catherine.howie@mmclintrials.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Jim Bartley</name>
      <address>Middlemore Hospital
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 211485077</phone>
      <fax />
      <email>j.bartley@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>